Association of Interleukin-4 Polymorphisms With Breast Cancer in Taiwan

Chu, Chin Nan; Wang, Yun-Chi; Chang, Wen‐Yu; Wang, Zhihong; Liu, Liang‐Chih; Wang, Shao‐Chun; Lin, Cheng‐Chieh; Liu, Ting-Yuan; Chang, Jan‐Gowth; Tsai, Chia-Wen; Yu, Chien‐Chih; Bau, Da‐Tian

doi:10.21873/invivo.11882

Cited by 8 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The function of this cytokine (IL-10) is altered when any type of alteration or polymorphism occurs in the promotor region, changing the downstream transcriptional activity signaling and cellular events result in the development of a human disorder. Previous studies show the polymorphism at IL-10 (-1082 G/A) was associated with osteosarcoma (Cui et al, 2015), lymphoma (Yu et al, 2014), gastric cancer (Kuo, 2014;Li et al, 2014;Ni et al, 2012), oral cancer (Tsai et al, 2014), nasopharyngeal carcinoma (Tsai et al, 2013). Another study shows the role of IL-10 (-1082 G/A) in the development of chronic lymphoid leukemia in the late stage among Russians (Ovsepyan et al, 2015).…”

Section: Discussionmentioning

confidence: 92%

Molecular Analysis of Interleukin-10 Gene for -1082 G/A Polymorphism in Breast Cancer Patients

Adamu¹

2023

PJZ

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 92%

Molecular Analysis of Interleukin-10 Gene for -1082 G/A Polymorphism in Breast Cancer Patients

Adamu¹

2023

PJZ

View full text Add to dashboard Cite

show abstract

“…The three genes examined in the current study are IL-1β, IL-4, and VEGF. Three alternative locations were chosen based on previously published datasets ( Eras et al, 2019 , Chu et al, 2020 , Rezaei et al, 2016 ). These Promoter region of included IL-1 (product length 240 nt), IL-4 (product length 334 nt), and 3′-UTR region of VEGF (product length 443nt).…”

Section: Methodsmentioning

confidence: 99%

Detection of IL-1β, VEGF and IL-4 with their novel genetic variations in breast cancer patients

Mohammed¹,

Qadir²

2023

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

“…The study was reviewed and approved by the Institutional Review Board of China Medical University Hospital (DMR99-IRB-108). Briefly, 2,464 subjects were recruited, including 1,232 female patients diagnosed with breast cancer and 1,232 age-matched healthy female visiting China Medical University Hospital as described in our previous publications (34,35). They were all Taiwanese covered by the national insurance health system.…”

Section: Methodsmentioning

confidence: 99%

Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility

Tsai

Chang

et al. 2020

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: The current study aimed at evaluating the contribution of IL-13 promoter rs1881457 and rs1800925 genotypes to the risk of breast cancer in Taiwan. Materials and Methods: A total of 1,232 breast cancer cases and 1,232 age-matched controls were genotyped by typical polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Results: As for IL-13 rs1881457, the rates of AA, AC and CC genotypes were 54.8, 37.9 and 7.3% among the cases, and 53.8, 38.7 and 7.5% among the healthy controls, respectively; there were no statistically significant differences between the two groups (p for trend=0.8889). Also, regarding IL-13 rs1800925, there were no statistically significant differences between the two groups either (p for trend=0.6803). Furthermore, the allelic frequencies for IL-13 rs1881457 and rs1800925 were not differentially distributed between the case and control groups (p=0.6515 and 0.8753, respectively). Conclusion: The rs1881457 and rs1800925 IL-13 promoter polymorphisms may not serve as breast cancer susceptibility determinants for Taiwanese.Breast cancer is the leading female malignant disease worldwide. In both genders combined in 2018, lung cancer was the most commonly diagnosed cancer (11.6% of the total cancer cases) and the leading cause of cancer-related death (18.4% of the total cancer deaths) followed by female breast cancer (11.6%) (1). Epidemiological studies indicate that breast cancer is caused by several environmental factors, including imbalanced diet, excessive alcohol drinking and cigarette smoking, and insufficient physical exercise (2, 3). In addition, genetic factors are also involved in breast cancer susceptibility, progression and prognosis (4-7).The gene of the immune-regulatory cytokine interleukin-13 (IL-13), cloned in 1993, is located on chromosome 5q31 and has a length of approximately 1.4 kb (8). The 13 kDa protein IL-13 is secreted predominantly by Th2 lymphocytes and natural killer T cells (9, 10). The role of IL-13 in tumor progression is complex, and it seems to function like a double-sided blade. Regarding tumor promotion, it has been previously reported that the decrease in IL-13 levels in CD1deficient mice lacking natural killer T cells may inhibit tumor recurrence (11-15). In addition, there is evidence that IL-13 may directly block apoptosis and promote proliferation of tumor cells in B chronic lymphocytic leukemia and Hodgkin disease (16)(17)(18)(19). Furthermore, a study has also indicated that CD4-positive T cell-derived IL-13 can 6743 *These Authors contributed equally to this study.

show abstract

Association of Interleukin-4 Polymorphisms With Breast Cancer in Taiwan

Cited by 8 publications

References 39 publications

Molecular Analysis of Interleukin-10 Gene for -1082 G/A Polymorphism in Breast Cancer Patients

Molecular Analysis of Interleukin-10 Gene for -1082 G/A Polymorphism in Breast Cancer Patients

Detection of IL-1β, VEGF and IL-4 with their novel genetic variations in breast cancer patients

Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility

Contact Info

Product

Resources

About